SLC5A2 and heart failure: After considering the baseline characteristics of the patients and therefore addressing potential confounding factors such as the overrepresentation of heart failure in the SGLT2-i group due to the prescription indication change during the analyzed period, the SGLT2-i therapy did not prove to be associated with a reduced infarct size.